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Abstract
Objective: The aortic valve replacement is a routine
procedure with acceptable risk, but in some cases, such a
risk can justify contraindication. The minimally invasive
transcatheter aortic valve implantation has been viable, with
lower morbidity and mortality. The aim of this study was to
develop a national catheter-mounted aortic bioprosthesis
for the aortic position implant.
Methods: After animal studies, 14 patients with high
EuroSCORE underwent transcatheter aortic valve
implantation. Median Logistic EuroSCORE was 43.7%. Four
patients presented with dysfunctional bioprosthesis,
remaining ones presented calcified aortic stenosis. All
patients presented symptoms. Procedures were performed
in a hybrid OR under fluoroscopic and echocardiography
guidance. Using a left minithoracotomy the prosthesis was
implanted through the ventricular apex under ventricular
pacing or hemorrhagic shock, after aortic valvoplasty.
Echocardiograph and angiograph controls were performed,
and the patients were referred to ICU.
Results: Implant was feasible in 13 cases. There were no
intra-operative deaths. Median peak transvalvular aortic
gradient reduced to 25.0 mmHg, and left ventricular function
improved in the first seven post-operative days. Paravalvular
aortic regurgitation was mild and present in 71%. No
definitive pacemaker was needed. There was no peripheral
vascular complication. Overall mortality was 42%.
Conclusion: The transapical implantation of catheter-
mounted bioprosthesis was a feasible procedure. Long term
follow-up is mandatory in order to access efficacy and
indications.
Descriptors: Aortic valve stenosis. Heart catheterization.
Extracorporeal circulation.
Resumo
Objetivo: A troca valvar aórtica é procedimento rotineiro
com risco aceitável. Em alguns casos, a mortalidade é
elevada, levando à contraindicação do procedimento, apesar
dos sintomas. O implante minimamente invasivo
transcateter de valva aórtica parece ser uma alternativa,
reduzindo a morbi-mortalidade. O objetivo deste estudo
foi o desenvolvimento e implante de nova prótese
transcateter.
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treatment. The survival rate with the technique was not
satisfactory with a mortality rate of 65% at 1 year. Only 40%
of patients at 1 year were free of reintervention, aortic valve
replacement surgery, heart block, or death [6].
In face of the unsatisfactory outcomes, several
initiatives have been proposed in order to develop a way
to implant a valve-based device in the aortic position capable
of providing more consistent and sustained results, while
allowing simultaneously the reduction of morbidity and
mortality imposed by the aortic valve replacement surgery.
The first description of a catheter valve implantation
was performed by Davies [7] in 1965. The idea was only
resumed several decades later when Andersen et al. [8] in
1992, described the experimental implant of a metal frame
on which were mounted cusps.
Only 10 years after the initial description by Andersen,
Cribier et al. [9] have described the first human implant in a
case of extreme severity. The immediate result was very
satisfactory, leading to a significant reduction of the
transvalvar gradient, improved of the ejection fraction, and
the clinical status of cardiogenic shock.
Studies using prototypes in cases considered to have
no conventional surgical alternative such as, I-REVIVE
(Initial Registry of Endovascular Implantation of Valves in
Europe) and RECAST (Registry of Endovascular Critical
Aortic stenosis Treatment), were carried out in 2003 and
2004 [10 ]. The initial success of the procedure was as high
as 75% with an increase of the valve area from 0.6 cm2 to 1.6
cm2, mean gradient reduction from 37 to 9 mmHg, and
improvement of the ejection fraction from 45% to 53%. The
30-day mortality rate was 23% and the rate of major
cardiovascular events was 26% [11].
The initial encouraging experience motivated several
multicenter studies, many of them not yet published, such
as the REVIVAL II (Transcatheter Endovascular
INTRODUCTION
The degenerative aortic valve calcification related to
aging is the most common cause of aortic stenosis in
developed countries. It is the most common evidence for
aortic valve replacement [1]. The prevalence of severe aortic
stenosis increases with age and may affect up to 2% of
individuals over 65 years of age [1].
There is an indication for surgery when the valve area
is less than 0.7 cm2, or the systolic gradient is higher than
50 mmHg, although the symptoms can begin earlier. Survival
after the onset of symptoms is as low as 60% at 1 year and
32% in five years [2].
The standard treatment is the surgery with
cardiopulmonary bypass and aortic clamping. Currently,
the aortic valve replacement is a well-known procedure with
consistent outcomes. The operative mortality rate is as low
as around 4% [3].
Despite the well-established outcome, the risk is higher
in some patients, especially the older ones. Besides the
age, several comorbidities also raise the surgical risk, thus
up to one third of patients have their procedure
contraindicated, although the symptoms or the presence
of structural cardiac impairment [4]. The existence of patent
coronary grafts, extensive thoracic irradiation, or a severely
atheromatous aorta, or porcelain aorta, multiple previous
operations, biological fragility, and the lack of symptoms
can be well documented reasons for refusal to intervene in
this special group of individuals.
In searching for alternatives to high-risk patients,
several groups have proposed options to conventional
valve replacement.
Aortic balloon valvuloplasty was proposed in 1996 by
Cribier et al. [5] as an alternative to patients considered
having unacceptable risk for conventional surgical
Métodos: Após desenvolvimento em animais, uma prótese
transcateter, balão-expansível foi utilizada em 14 casos de
alto risco. O EuroSCORE médio foi de 43,7%. Quatro
pacientes apresentavam disfunção de biopróteses e o
restante, estenose aórtica calcificada. Todos os pacientes
eram sintomáticos. Os procedimentos foram realizados em
ambiente cirúrgico híbrido, sob controle ecocardiográfico e
fluoroscópico. Com o uso de minitoracotomia esquerda, as
próteses foram implantadas através do ápice ventricular, sob
estimulação ventricular de alta frequência ou choque
hemorrágico controlado, após valvoplastia aórtica. Foram
realizados controles clínicos e ecocardiográficos seriados.
Resultados: A correta liberação da prótese foi possível em
13 casos. Uma conversão ocorreu. Não houve mortalidade
operatória. O gradiente de pico médio pós-implante foi de
25 mmHg. A fração de ejeção apresentou aumento
significativo após o 7º pós-operatório. Insuficiência aórtica
residual não significativa esteve presente em 71% dos casos,
nenhuma significativa. Não ocorreu complicação vascular
periférica. Não houve necessidade de marcapasso definitivo.
Um caso de acidente vascular cerebral ocorreu. A mortalidade
geral foi de 42%.
Conclusão: O implante transapical de valva aórtica
transcateter é um procedimento possível com esta nova
prótese. O comportamento hemodinâmico foi satisfatório.
São necessários estudos de longo prazo e com maior poder
amostral, no intuito de determinar a real eficácia e indicação
do procedimento alternativo.
Descritores: Estenose da valva aórtica. Cateterismo
cardíaco. Circulação extracorpórea.
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Implantation of Valves II) and REVIVE II (Registry of
Endovascular Implantation of Valves in Europe II). The initial
enthusiasm evoked by the results promoted the adoption
of these devices by regulatory authorities, allowing the
initiation of a multicenter randomized study called PARTNER
(Placement of Aortic Transcatheter) [12].
In our country, there are no prosthetic valve aortic
devices of transcatheter implantation available with national
manufacturing and technology. Using the development of
aortic stent with national technology as a model, which
allowed the general population to have a larger access to
these restricted techniques, the Discipline of
Cardiovascular Surgery, at the Federal University of São
Paulo started to develop a project of an aortic valve
prosthesis for transcatheter implantation in partnership with
the private sector (Braile Biomedica, São José do Rio Preto)
and  the FAPESP - The São Paulo State Research Support
Foundation, an State Agency the aim of providing grants,
funds and programs to support research, education and
innovation of private and public institutions and companies
in the state of São Paulo. The differential this prosthesis is
based on the fact that the structure of the pericardium can
be made with no need of intermediate sutures, probably
increasing the resistance to wear and tear of the material.
The evaluation of clinical results of this initiative is the
focus of this work.
METHODS
The clinical protocol only began after the selection
phase of a suitable experimental model (Figure 1), with
adequate hemodynamic performance, durability, and
security.
Flow duplicators were used to test the enduringness of
the device. The parameters used were the same ones used
in the conventional bioprosthesis. The animal experimental
phase consisted of implants in pigs during a 3-month
echocardiographic and angiographic follow-up.
The prosthesis consists of an electrochemically-
polished, balloon-expandable stainless steel frame-like
structure. Internally, a bovine pericardial bioprosthesis was
assembled, with structure and arrangement similar to the
conventional bioprostheses, without splicing points
between the leaflets. The diameters ranged from 20 mm to
26 mm. The mechanism for setting the valve ring is a
composition of the endoprosthesis radial force and calcium
interaction with the valve structure.
Between June 2008 and November 2009, 14 patients
underwent transcatheter aortic valve implantation. The
institutional Ethics Committee (CEP 1116/08) approved the
study and protocol. Patients provided the free written
informed consent.
Patients were selected by a multidisciplinary group that
included cardiovascular surgeons, clinical cardiologists,
hemodynamicists, and anesthesiologists. The selection of
patients involved, in addition to multidisciplinary
consultation and the criteria for inclusion and exclusion,
the importance of aspects such as the surgical risk,
expectation and quality of life.
The risk scores EuroSCORE and STS SCORE was used
in order to provide a quantitative analysis on the individual
risk involved in the procedure.
Patients underwent the following exams: clinical,
laboratory, echocardiography, cineangiocoronariography
(when the clinical condition allowed), and Doppler
ultrasonography of carotid, femoral and iliac arterial
systems.
Fig. 1 -  Balloon-expandable device for insertion in the aortic
position
Inclusion Criteria
1. Patients with exacerbated comorbidities that both
teams, the cardiovascular surgery and the cardiology agreed
that the mortality risk predicted for conventional
intervention was higher than 15% predicted by the
EuroSCORE and / or greater than 10% predicted by the
STS SCORE;
2. Presence of senile degeneration of the aortic valve
with severe stenosis (mean gradient > 40 mmHg, jet speed
higher than 4 m/s, or valve orifice < 0.8 cm2), or dysfunction
of bioprosthetic with significant valve failure;
3. Symptomatic patients due to valve stenosis or
prosthetic valve dysfunction, with functional class e” II
according to the New York Heart Association (NYHA).
 
GAIA, DF ET AL - Transapical aortic valve implantation: results of
a Brazilian prosthesis
Rev Bras Cir Cardiovasc 2010; 25(3): 293-302
296
Exclusion Criteria
1. Evidence of acute myocardial infarction in a time
interval < one month;
2. Unicuspid or bicuspid  aortic valve;
3. Noncalcified aortic valve;
4. Native valve dysfunction with mixed component
(stenosis and failure) with predominant regurgitation or > 3+;
5. Invasive cardiac procedures in the last 30 days (6
months after implantation of drug-eluting coronary stent);
6. Moderate to severe, or severe mitral regurgitation;
7. Nontreated significant coronary artery disease
requiring surgical revascularization;
8. Obstructive hypertrophic cardiomyopathy;
9. Evidence of intracardiac mass (tumor, thrombus, or
vegetation);
10. Active peptic ulcer disease;
11. Hypersensitivity or contraindication to platelet
antiaggregation or in the contrast medium;
12. Aortic annulus diameter <16 mm or > 24 mm;
13. Stroke or recent transient ischemic attack (within
the last 6 months);
14. Life expectancy < 12 months due to noncardiac
disease or other comorbidities;
15. Presence of unstable and sessile atheromas in the
ascending aorta and/or in the aortic arch found by
transesophageal echocardiography, computed tomography.
Demographic characteristics and comorbidities of the
patients are listed in Table 1.
A catheter-mounted aortic valve with a diameter 20%
larger than the aortic valve annulus measured through
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Table 1. Comorbidities and demographic characteristics.
Characteristics
Age in years (mean/interval)
Female gender (n/%)
Diabetes (n/%)
Glomerular filtration rate < 50 mL/min (n/%)
Dialytic renal insufficiency
Restrictive/obstructive pulmonar disease (n/%)
Recent Pneumonia (n/%)
Undergoing surgery while still hospitalized due to decompensation (n/%)
Undergoing surgery while still hospitalized due to decompensation – 1st half of the sample (n/%)
Undergoing surgery while still hospitalized due to decompensation – 2nd  half of the sample (n/%)
Atrial fibrillation (n/%)
Functional Classe (n/%)
II
III
IV
Comorbidities
Coronary arterial disease (n/%)
Previous AMI (n/%)
Previous PTCA (n/%)
Previous MR prévia (n/%)
Peripheral arterial diseasae (n/%)
Previous Stroke (Previous cerebrovascular accident) (n/%)
Cancer (n/%)
Porcelain aorta (n/%)
Chagas (n/%)
Sickle cell anemia (n/%)
Reoperation (n/%)
“Valve-in-valve” (n/%)
Logistic EuroSCORE (%) (mean/interval)
Logistic EuroSCORE (%)1st half of the sample (mean/interval)
Logistic EuroSCORE (%) 2nd  half of the sample (mean/interval)
STS score (%) (mean/interval)
STS score (%)1st half of the sample (mean/interval)
STS score (%) 2nd  half of the sample (mean/interval)
Peak aortic gradient
Mean aortic gradiente
Left ventricle ejection fraction
n=14
75.7 / 34-88
6 / 42.8
3 / 21.4
12 / 85.7
0
5 / 35.7
3 / 21.4
6/ 42.8
4/ 57.1
2/ 28.5
2 / 14.2
3/21.4
6/42.8
5/35.7
4/28.5
3/21.4
2/14.2
1/7.1
4/28.5
0
0
0
1/7.1
1/7.1
6/42.8
5/35.7
43.7/12,4-74.9
42.6/13.7-64.8
44.8/12.4-79.6
37.4/8.3-61.1
37.8/8.3-61.1
37.1/17.1-51.8
79.7±4.8
45.3±4.2
47.6±3.5
PTCA - Percutaneous transluminal coronary angioplasty
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transesophageal echocardiography was positioned on a
catheter-balloon with a diameter compatible with its
maximum aperture and compacted with the aid of a radial
compressor device.
After anesthetic induction, the patient was positioned
in a supine position, with a pad under the left scapula. The
right inguinal region was dissected to isolate the femoral
artery and vein in order to allow the secure peripheral
cannulation. Previous cannulation and preparation of the
cardiopulmonary bypass machine were carried out to enable
greater security to the procedure with the immediate entry
into perfusion in the eventuality of an accident during the
procedure, besides providing controlled hypotension
during the opening of the valve device in nine cases.
Heparin at a dose of 4 mg/kg was administered in order to
achieve an activated clotting time (ACT) above 400 seconds.
The right femoral artery was punctured using the
Seldinger technique, and a 6-Fr introducer was positioned.
A catheter was advanced into the aortic root with the aid of
a guide wire, in order to allow the performance of control
aortographies before and after prosthetic valve opening,
besides identifying the aortic sinuses and coronary ostia.
The ventricular apex was identified by transthoracic
echocardiography. At the marked site, an incision of
approximately 5 cm in length was performed to obtain access
to the ventricular apex.
The 6-Fr introducer was withdrawn, and a 24-Fr
introducer was placed into position. A balloon catheter of
appropriate diameter was placed on the aortic valve. Then,
we carried out a controlled hypotension with the aid of
venous drainage for cardiopulmonary bypass support, or
a ventricular stimulation with a high-frequency pacemaker
(180-200 bpm). Thereafter, the balloon was inflated to its
maximum nominal pressure in order to promote aortic
valvuloplasty (Figure 2).
The balloon was deflated. The pressure restored and a
control echocardiogram performed to confirm the
effectiveness of valvuloplasty. The balloon was then
Fig. 2 - Aspect of the purse-string suture and the preparation to
place the 24-Fr introducer
Fig. 3 - Inflation of the balloon catheter and the prosthesis opening.
Fluoroscopy
removed and replaced over the same guide wire by the
valve prosthesis mounted previously.
A new episode of controlled hypotension was carried out
and then the balloon catheter with the prosthesis mounted
was inflated to its maximum nominal pressure by promoting
the release of the prosthesis (Figure 3). Its rapid deflation
allowed the restoration of blood pressure with the replacement
of the drained volume or the suspension of ventricular
stimulation. If a transesophageal echocardiogram showed
leakage around the prosthesis, a new episode of balloon
inflation was performed under controlled hypotension.
A control aortography documented the correct
functioning of the prosthesis and a possible interference
Fig. 4 - Control aortography demonstrating the patency of the
coronary ostia and no significant aortic insufficiency
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with the coronary filling, in cases of doubt with the use of
echocardiogram (Figure 4).
The introducer was removed and the ventricular apex
occluded using the purse-string suture. The patient was
awakened from anesthesia when the clinical conditions were
favorable and referred to the intensive care unit.
The procedure success was defined as a correct implant,
satisfactory hemodynamic profile, no valve or perivalvular
significant leaks, and immediate lack of major complications.
Statistical analysis was performed using SPSS version
11. The confidence level of 0.05 was used as significant.
The comparison between the means used the Friedman test,
after verifying the normal distribution of values. The mean
and standard error were used to express the analysis, unless
specified otherwise. The analysis of hemodynamic data
excluded the following cases: patient 2 who undergone
conversion to the conventional procedure; patient 9 died
before 30 days of follow-up; and patients 12, 13, 14 because
they do not complete 30 days of follow up at the moment of
completion of this study.
RESULTS
All cases were performed at the Federal University of
São Paulo - Paulista School of Medicine in a hybrid
operating room. The successful valve implantation was
possible in 13 cases. There was only one immediate
conversion to prosthesis migration. No intraoperative
deaths occurred.
We used the following sizes of devices: 3 (20 mm), 6 (22
mm), 2 (24 mm), and 2 (26 mm). The cases of valve-in-valve
used two prostheses of 20 mm and three of 22 mm, respectively.
All patients survived the procedure, and the overall
mortality rate was 42.8%. There was one death within the
first 30 days of follow up due to a related complication
(stroke). There were five in-hospital deaths (before
discharge). These were resulting from clinical complications
not directly related, including bronchopneumonia (three
cases) and tracheoesophageal fistula (one case). Only one
of the individuals who were discharged from the hospital
died during follow-up due to Influenza A H1N1. The mortality
of the second half of the sample was 14.2%.
The result hemodynamic assessed by echocardiography
was satisfactory, with a significant reduction of the peak
gradient from 79.7 ± 9.9 to 25.0 ± 5.2 mmHg on the first
postoperative day (P = 0.0058). The outcome showed that
the reduction of the gradient was maintained in subsequent
examinations, with no statistically significant difference
between the gradient obtained after implantation in the
immediate postoperative period. The gradient also showed
a significant reduction from 40.1 ± 7.3 mmHg to 10.7 ± 2.0
mmHg on the first postoperative day (P = 0.0001). The
development also demonstrated the maintenance of this
reduction (Figure 5).
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Fig. 5 - A. Aortic transvalvular peak gradients preoperatively;on  postoperative day 1, postoperative day 7, and postoperative day 30. B.
Mean aortic transvalvular gradients on the preoperative period, on postoperative day 1, postoperative day 7, and postoperative day 30
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Periprosthetic aortic regurgitation has occurred in most
cases. Four patients showed no reflux (all valve-in-valve);
six, mild insufficiency; and four mild to moderate
insufficiency.
The ventricular function measured through the left
ventricle ejection fraction using Simpson’s method showed
statistically significant improvement from 44.46 ± 3.4 to 56.8
± 3.3, on the seventh day after surgery (P = 0 , 0001),
sustained on the follow-up period (Figure 6).
hemothorax on the left, probably secondary to apical
ventricular bleeding requiring chest tube drainage without
the need for surgical re-exploration, and the third one also
had pleural effusion on the left, requiring thoracentesis.
DISCUSSION
The aortic valve replacement is the procedure of choice
in patients with aortic valve stenosis or dysfunction of
bioprostheses symptomatic with high gradient. This
procedure is well established in the literature and their
results favorable and consistent, even in higher age groups
and patients with multiple comorbidities [13-15].
Although meeting the well-defined criteria for the
indication of the procedure, approximately 30-60% of
patients may have a surgical indication denied because
they are considered to be at high risk [2,16].
There are many reasons for the contraindication to the
conventional procedure, including the following: the
presence of extensive calcified or porcelain aortas, the
presence of patent coronary grafts, thoracic radiotherapy,
or the existence of multiple comorbidities. The assessment
of these patients’ operative risk is based on several scores,
which seek to predict mortality for a given patient
undergoing a surgical procedure, besides, of course, the
personal perception of the care team.
There are several limitations of the risk scores, among
them the non-inclusion of some features considered as risk
for intervention, such as mediastinal irradiation, porcelain
aorta, liver dysfunction, abnormalities of the chest wall,
and previous mediastinitis. It should be taken into account
that the individuals which served as the basis to compose
the scores were actually undergoing the surgery, limiting
the inference in groups that were not originally considered
candidates for interventional procedure [17].
Important part of the cases consisted of reoperated
patients, which is known to increase the risk of a new
intervention. Despite this, reports demonstrated the safety
and efficacy of transcatheter intervention in this group of
patients who have not only valve reinterventions, but aortic
and coronary artery reinterventions as well [18]. Thus, this
particular group is especially benefited by the new
alternative.
Unlike the literature, our patients had comorbidities as
yet not described, such as Chagas disease and sickle cell
anemia and therefore not compared to the international risk
scores, demonstrating the need to individualize the risk
stratification and adapt it to our environment. Another very
much younger patient than those reported in previous cases
in the literature presented extremely high-risk score, multiple
comorbidities, four cardiovascular reoperations, and sickle
cell anemia polysensitised by blood products, highlighting
the fact that younger patients with high-risk of
Table 2. Operatory variables.
Variable
Successful procedure (n/%)
Conversion to conventional replacement (n/%)
Ressuscitation
Defibrillation (n/%)
Entry on cradiopulmonary bypasss support
Contrast (mL)
Fluoroscopy time (min)
Procedute time (min)
n=14
13/92.8
1/7.1
0
2/14.2
2/14.2
80±9.4
16.5±1.9
217.7±26.6
No patient had a complete atrioventricular block or need
a permanent pacemaker implantation.
The intraoperative variables are listed in Table 2.
It was required the cardiopulmonary bypass support in
a case with conversion to a conventional procedure and in
one case without conversion.
Three patients required readmission after discharge.
One patient showed a lobar pneumonia. Another had a
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Fig. 6 - Ejection fraction of left ventricle preoperatively, on
postoperative day 1, postoperative day ,7 and postoperative day 30
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reintervention may benefit technique. From then on, a new
group can be formed in which this procedure will serve as
a bridge to partial recovery, clinical improvement and
provision of more satisfactory conditions for definitive
conventional therapy.
The occlusion of the left ventricular apex after
manipulation with large caliber introducers is another
challenge. The non-use of cardiopulmonary bypass support
may cause difficulty in apical hemostasis with consequent
blood loss. Perhaps the two cases of hemothorax in the
study may have been the result of a slow apical bleeding
with spontaneous resolution.
Although the atrioventricular block is a relatively
common complication, a permanent pacemaker implantation
was not required. The Balloon-expandable prosthesis, such
as the Edwards Sapien THV (Edwards Lifesciences, Irvine,
CA) had need indexes of permanent cardiac stimulation of
7% [12]. The auto-expandable prostheses such as the
CoreValve (CoreValve, Irvine, California) presented
complete atrioventricular block rate relative higher reaching
as much as 24% [12].
The conversion needs to median sternotomy, total
cardiopulmonary bypass support, and conventional valve
replacement has been described as around 1.2% [12]. This
study presented only one case of conversion; however,
the small number of patients in our study may have not
permitted adequate statistical comparisons. The cause of
conversion was directly related to the learning curve.
Several groups have demonstrated the persistence of
various degrees of aortic insufficiency after the procedure,
mainly from perivalvar origin, usually ranging from mild to
moderate degree [19]. The prevalence of failure is higher
than expected to conventional substitutions [20,21]. Given
the irregularity of the circumference of the aortic valve
annulus after balloon valvuloplasty, the presence of failure
is not surprising due to the difficulty encountered by the
prosthetic device to perform a perfect coaptation with the
valve annulus calcification. On the other hand, the presence
of extensive calcification of the annulus appears to be a
decisive factor in the adequate support of the prosthesis,
thus helping to prevent further migration of the device.
Data from the International Registry of Edwards Sapien
showed a 45% failure of 1+, 32% of 2+, and 7.5% of 3+ for
prostheses with a 23 mm-diameter. With the use of 26 mm-
diameter prosthesis, there were no failures of 3+, but 50.8%
and 36.1% showed failure of 1+ e 2+, respectively [12]. In
this series, the aortic insufficiency was comparable to the
results of the record cited using 26 mm-diameter prostheses.
Probably, the availability of a greater number of prosthetic
diameters may have allowed more precise selection of a
suitable model capable of better coaptation in relation to
the native valve annulus. Patients undergoing valve-in-
valve implant showed no aortic insufficiency perivalvar by
coaptation, naturally more regular between the two
prostheses.
The current data do not allow conclusions about the
impact on survival or the ventricle performance, as well as
the occasional need for reintervention caused by the
presence of residual aortic insufficiency. It can be assumed
that the behavior should resemble to light native
insufficiencies, unless it causes hemolysis, and it requires
the need for conventional intervention and the replacement
of the transcatheter prosthesis by a conventional
bioprosthesis [20,21]. Accepting the presence of an aortic
insufficiency as a natural consequence and part of the
procedure, rather than seeing it as a complication, is part of
the paradigm changing that involves the transcatheter
aortic valve treatment.
All the transvalvular gradients after implantation were
low, demonstrating a favorable hemodynamic profile of the
new device. It is possible that the gradients of these new
devices are even lower than those expected to the
conventional bioprostheses and these devices might have
larger effective valve orifices probably due to their
prostheses constructive features. These features can
contribute positively to a better hemodynamic performance
during follow-up, and they can be translated into the
possibility to increase survival rates [22].
The improvement in ventricular function is compatible
with that expected after stenosis removal and the reduction
of the ventricular ejection gradient in patients with the
presence of functional reserve. The study could suggest a
regression of ventricular dysfunction, just as had been
shown in a short time [11.23]. This improvement is faster,
but comparable in final absolute terms to the conventional
replacements [22]. The rapid improvement may explain, in
part, the differences in the mortality rate observed between
transcatheter and conventional procedures. The possible
causes of this difference do not include the use of
cardiopulmonary bypass support and aortic clamping under
cardioplegic protection, and the presence of a lower
afterload generated by transcatheter prostheses [22].
The in-hospital mortality rate of the procedure is
inconstant, but lower than predicted by the risk scores,
ranging between 23% [10] and 6.3% [12]. Indeed, the
mortality rate in our series is high, which may be caused by
a small number of individuals, as well as the selection of
severe patients, which becomes evident in the analysis of
the mean EuroSCORE and STS SCORE of the study
population.
The stratification of our mortality rate after half of the
experience makes it clear that there is a definite learning
curve in the patient selection and in the performance of the
procedure. The severity of the individuals remained high
in both halves with no significant difference between them.
It is also worth mentioning that the first half of the sample
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